Elicera Therapeutics

3.25 SEK

-2.99 %

Less than 1K followers

ELIC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-2.99 %
-38.54 %
-42.05 %
-37.84 %
-47.91 %
-4.28 %
-10.11 %
-
-47.66 %

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.

Read more
Market cap
157.5M SEK
Turnover
415.43K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.5
2026

General meeting '26

5.5
2026

Interim report Q1'26

8.5
2026

Extraordinary general meeting '26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.